XML 33 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Intangible Assets
 9 Months Ended
Sep. 30, 2018
Intangible Assets, Net (Excluding Goodwill) [Abstract]  
Intangible Assets
Intangible assets

The following table summarizes the Company's Intangible assets:
(In millions)
Currently marketed products
 
IPR&D
 
Other intangible assets
 
Total
September 30, 2018
 
 
 
 
 
 
 
Gross acquired intangible assets
$
33,767.4

 
$
1,012.7

 
$
830.8

 
$
35,610.9

Accumulated amortization
(5,561.2
)
 
—

 
(424.3
)
 
(5,985.5
)
Intangible assets, net
$
28,206.2

 
$
1,012.7

 
$
406.5

 
$
29,625.4

 
 
 
 
 
 
 
 
December 31, 2017
 
 
 
 
 
 
 
Gross acquired intangible assets
$
31,973.5

 
$
5,113.9

 
$
835.9

 
$
37,923.3

Accumulated amortization
(4,549.2
)
 
—

 
(328.0
)
 
(4,877.2
)
Intangible assets, net
$
27,424.3


$
5,113.9


$
507.9


$
33,046.1



During the third quarter of 2018, the U.S. Food and Drug Administration (FDA) approved TAKHZYRO injection, for prophylaxis to prevent attacks of HAE in patients 12 years of age and older. Following the approval, the Company reclassified the TAKHZRO intangible asset from IPR&D to Currently marketed products and started amortizing the asset.

Other intangible assets are comprised primarily of royalty rights and other contract rights associated with Baxalta, Dyax Corp. (Dyax), and NPS Pharmaceuticals Inc. 

Activities in the net book value of intangible assets for the nine months ended September 30, 2018 and 2017 are as follows: 
(In millions)
2018
 
2017
As of January 1,
$
33,046.1

 
$
34,697.5

Sale of Oncology franchise
(1,598.5
)
 
—

Measurement period adjustments
—

 
(1,397.0
)
Amortization charged
(1,375.3
)
 
(1,280.5
)
Foreign currency translation
(314.2
)
 
1,350.3

Contribution to JV
(163.7
)
 
—

Impairment
(10.0
)
 
(20.0
)
Other
35.9

 
—

Acquisition
5.1

 
—

As of September 30,
$
29,625.4

 
$
33,350.3

 

Measurement period adjustments included in the nine months ended September 30, 2017 related to the acquisition of Baxalta.

For further details regarding the sale of the Oncology franchise, refer to Note 5, Dispositions and Assets Held for Sale.

During the nine months ended September 30, 2018, the Company contributed distributions rights for certain products to a joint venture formed by the Company. Upon the contribution, the net carrying value ($163.7 million) related to those products was recorded within Investments in these Unaudited Consolidated Balance Sheets.

The Company reviews its amortized intangible assets for impairment whenever events or circumstances suggest that their carrying value may not be recoverable. Unamortized intangible assets are reviewed for impairment annually or whenever events or circumstances suggest that their carrying value may not be recoverable.

Estimated amortization expense can be affected by various factors including future acquisitions, disposals of product rights, regulatory approval and subsequent amortization of acquired IPR&D projects, foreign exchange movements, and the technological advancement and regulatory approval of competitor products. The estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:

(In millions)
Anticipated future amortization
2018 (remaining three months)
$
444.4

2019
1,808.0

2020
1,730.7

2021
1,710.9

2022
1,679.3

2023
1,627.3